Expert Opinions

Legacy Device Security: Who Owns the Risk After Support Ends?

Listen to this article · 8 min listen

Connected health devices often outlive their marketing and support periods, which creates a massive, ill-defined security liability gap. For those of us in health tech compliance and security, getting through this mess means knowing the regulatory expectations inside and out, especially when it comes to figuring out who’s left holding the bag when a device becomes a “legacy” product. This is a particularly nasty problem now that healthcare is leaning so heavily on AI-driven tools, many of which are classified as Software as a Medical Device (SaMD).

The Evolving Field of Legacy Device Security

When a vendor stops actively marketing or supporting a connected device, the security risks don’t just magically disappear. A recorded post from Medcrypt, “Legacy Devices and FDA Cybersecurity: What You Need to Know,” gets right into this messy challenge, looking at how the FDA and various standards bodies are trying to handle these “legacy” and “end-of-support” devices. Medcrypt frames the central problem perfectly: who is responsible for security once the vendor walks away? It’s not a settled issue, and the post doesn’t pretend to have a final answer. For any hospital or clinic, the headaches are real. An unsupported device, even one that works perfectly fine, can quickly become your network’s weakest link if it isn’t managed correctly. This is especially dangerous in environments governed by HIPAA, where a data breach from an insecure old system can bring on severe financial penalties. AI-enabled devices make this even harder because you’re dealing with things like algorithmic drift on top of everything else, demanding constant monitoring that the original vendor is no longer providing.

Regulatory Frameworks and Ongoing Security Responsibility

The FDA’s cybersecurity guidance has been signaling for a while that device security is a continuous process, not just a checkbox to tick before going to market. While there’s no single, perfect definition of a “legacy device,” the core principle is clear: any device connected to patient data or a clinical network has to have a defensible security posture for its entire operational lifespan. The FDA’s latest final guidance, “Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions,” issued in February 2026, reinforces this by tying it to the Quality Management System Regulation (QMSR) that went into effect on February 2, 2026. Standards bodies are also piling on, working with regulators to set expectations. They’re the ones providing practical frameworks for things like risk management, vulnerability disclosure, and secure development lifecycles that must apply even after a device stops getting official vendor updates. All these guidelines are pointing toward a shared responsibility model, though it’s often distributed in a way that makes it hard to pin down. As a compliance owner, you have to read between the lines of these evolving standards to build your own internal policies for managing devices at their end-of-life. That means having clear protocols for vulnerability management, patching when you can, and (most importantly) securely taking these devices offline for good.

Akili Interactive and the FDA’s Enforcement Reach

If you want to see how regulatory expectations play out in the real world, just look at the FDA’s enforcement history with device makers. The case of Akili Interactive, a digital therapeutics company, is a good example. Its public record includes references to FDA Cybersecurity Guidance that shows exactly how the agency communicates its demands and enforces them. (Virtual Therapeutics acquired Akili Interactive in 2024). An FDA Warning Letter, for example, isn’t just a suggestion, it shows the agency has serious concerns and has the teeth to sanction manufacturers for security failures. That scrutiny absolutely extends past the day a device first gets market clearance. Now, imagine a device with a prior Warning Letter on its record is now unsupported. The liability questions get magnified, raising serious doubts about who’s accountable for vulnerabilities that pop up after the vendor’s support contract ends. This kind of scenario is exactly why your vendor evaluation process has to cover the entire product lifecycle, including asking tough questions about planned end-of-support dates and the vendor’s long-term strategy. FDA guidance on postmarket cybersecurity for medical devices

The Unsettled Question of Responsibility

Even with all the new guidance and enforcement actions, who’s actually responsible for securing legacy, unsupported devices is still an open question. Medcrypt’s recorded material says this outright, admitting the issue is genuinely unresolved. This ambiguity is a serious challenge for anyone working in health tech compliance and security. What happens when a critical vulnerability is discovered in an AI-powered diagnostic tool that’s been out of support for years? Who has to fix it? Is it the original manufacturer’s problem, even a decade later? Is it the hospital’s for continuing to use it? Or is it some messy, shared responsibility that requires proactive risk management from everyone involved, even if there’s no contract that says so? With no definitive rule to follow, the only option is to be proactive and assume the worst. That means you have to get your own house in order.

  • Complete Inventory and Lifecycle Management: Keep a full inventory of every connected device, noting its support status and its planned end-of-life date.
  • Risk Assessment for Legacy Devices: Regularly assess the risks from your unsupported devices, looking at how they’re connected to the network, what kind of data they handle, and the potential for patient harm.
  • Diligence in Procurement: When you’re buying new tech, your vendor evaluation has to include detailed questions about end-of-support policies and long-term security. As part of your due diligence, you should be digging into a vendor’s history of FDA correspondence, including any Warning Letters.
  • Contingency Planning: Have a clear plan ready for isolating, replacing, or securely decommissioning any unsupported device that poses an unacceptable risk. NIST cybersecurity framework for medical devices The existing material isn’t going to assign blame for you, which leaves healthcare organizations with the burden of interpreting these risks and trying to mitigate them. Because there’s no clear, legally defined liability structure, the only pragmatic approach is to take on the responsibility for patient safety and data security yourself, regardless of a device’s official support status.

    Working through the Path Forward for Health Technology Compliance

    For health technology compliance and security owners, this isn’t a theoretical debate. It’s an immediate operational fire drill. The discussion being framed by Medcrypt, paired with the real-world enforcement context you can see in Akili Interactive’s FDA record, shows that this is a live regulatory and operational battle. As AI workflow regulations in healthcare get written and the FDA refines its position on AI health tools, the pressure to maintain tight security across the entire device ecosystem is only going to grow. Think about it: a HIPAA compliant AI health app needs to prove it has ongoing security, and that expectation has to cover its entire lifespan. So if you’re vetting a HIPAA compliant digital health platform, you have to scrutinize the vendor’s strategy for long-term security and what happens at the end of support, not just its current compliance certificate. The lack of a clear answer on who holds the ultimate responsibility means healthcare entities have to be vigilant and proactive to protect patient data and keep clinical operations from grinding to a halt. HIPAA Security Rule guidance

Frequently Asked Questions

What is the primary security concern for connected health devices after they reach end of support?

The primary security concern is that an unsupported device, even if fully functional, can become a significant vulnerability. This is especially true in regulated environments like HIPAA, where data breaches from insecure legacy systems can lead to severe penalties.

Does the FDA’s guidance on device security apply to devices that are no longer actively supported by their vendors?

Yes, the FDA has consistently signaled that device security is a continuous process, not a one-time assessment. Devices connected to patient data or clinical environments must maintain a defensible security posture throughout their operational lifespan, regardless of vendor support status.

Who is ultimately responsible for the security of legacy or end-of-support devices?

The precise allocation of security responsibility for legacy, unsupported devices remains an open question, as stated by Medcrypt. This ambiguity means healthcare organizations must adopt a proactive and risk-averse stance, as responsibility can be shared among manufacturers and healthcare providers.

What are the implications for healthcare organizations if a critical vulnerability is found in an unsupported device?

If a critical vulnerability is discovered in an unsupported device, it poses a significant challenge regarding who is responsible for mitigation. This scenario highlights the need for proactive risk assessment, mitigation strategies, and rigorous vendor evaluation frameworks that extend to the entire product lifecycle.

Share
Was this article helpful?

Editorial Team

The Editorial Team at HIPAA AI Health is a group of writers and editors who cover health, workplace wellness, and everyday care. They research each story and publish under a shared desk byline — experts in their fields, working as one team.